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The discovery of T-cell responses to SARS-CoV-2 in non-infected individuals indicates
cross-reactive immune memory from prior exposure to human coronaviruses (HCoV) that
cause the common cold. This raises the possibility that “immunity” could exist within
populations at rates that may be higher than serology studies estimate. Besides
specialized research labs, however, there is limited ability to measure HCoV CD4+ and
CD8+ T-cell responses to SARS-CoV-2 infection, which currently impedes interpretation
of any potential correlation between COVID-19 disease pathogenesis and the calibration
of pandemic control measures. Given this limited testing ability, an alternative approach
would be to exploit the large cohort of currently available data from which statistically
significant associations may be generated. This would necessitate the merging of several
public databases including patient and contact tracing, which could be created by
relevant public health organizations. Including data from both symptomatic and
asymptomatic patients in SARS-CoV-2 databases and surveillance systems could
provide the necessary information to allow for more informed decisions.
Keywords: SARS-CoV-2, COVID-19, T-cell, human coronaviruses, immunity, contact tracing, childrenINTRODUCTION—ASYMPTOMATIC INFECTION IN DENSE
POPULATIONS
It is most curious that the majority of poor, highly populated countries have seen fewer deaths per
million during the current pandemic than most advanced Western nations. In contrast, during the
1918 influenza pandemic, which had a global death rate approaching 3%, less-developed countries
saw noticeably higher rates (Spreeuwenberg et al., 2018). The large variation in SARS-CoV-2 deaths
per million people between countries, and even states and counties within the U.S., are on the
surface confusing and difficult to explain. It seems counterintuitive that countries with both limited
health resources and sick, aging populations have reported far fewer mortalities due to SARS-CoV-2
than countries with advanced healthcare resources, relatively healthy populations and greater lock-
down measures (Worldometer; Contributors W; Engineering JHUCfSSa, 2020) (Table 1).gy | www.frontiersin.org December 2020 | Volume 10 | Article 6053341
Capoor et al. Colds Our Ally Against SARS-CoV-2While a number of factors may explain this anomaly, including
differences in age, co-morbidities, socio-economic status, and
testing capacity, it should not be overlooked that individuals in
these poorer countries, who often reside in crowded multi-
generational family groups with shared facilities, may have
experienced increased and possibly sustained, exposure to
human coronaviruses (HCoVs) that cause the “common cold”.
This elevated exposure, which may lead to greater levels of cross-
immunity to SARS-CoV-2, may help explain why:
• A serology study of slums in three wards of Mumbai showed
that residents there had 3·5 times the SARS-CoV-2 infection
rate of those in housing societies (57% versus 16%), but lower
fatality rates (0·05%–0·10%) (Malani et al., 2020). None of the
people included in the study had been tested for active SARS-
CoV-2 infection using an RT-qPCR assay, suggesting either
asymptomatic infection or very mild symptoms.
• A study of the United States state prison systems in Arkansas,
North Carolina, Ohio, and Virginia revealed a 70% infectionFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 2rate amongst the 4,693 inmates tested, of whom 96% were
asymptomatic. A significant number of these prisoners were
older and, therefore, presumed to be more prone to
complications, but this was not the case (So and Smith, 2020).
• Approximately 90% of 147 homeless shelter residents in
Boston who were infected with SARS-CoV-2 exhibited no
symptoms, even though the shelter’s living space was shared
by all residents. Similarly, 95% of the 481 infected workers at a
Tyson Foods poultry plant in Springdale, Arkansas were
asymptomatic (Cha, 2020).ASYMPTOMATIC INFECTION IN
SCHOOL CHILDREN
Schools are densely populated environments, so their reopening
has left many people anxious about the role they may play in























Spain 46,754,778 30 0.6% 43,131 922.5 1 Bronx NY 1,432,132 28 0.4% 5,033 3514.3 1
Italy 60,461,826 23 0.8% 50,453 834.5 2 Queens NY 2,278,906 11 0.7% 7,338 3220.0 2
UK 67,886,011 21 0.9% 55,327 815.0 3 Kings NY 2,582,830 9 0.8% 7,481 2896.4 3
Argentina 45,741,007 31 0.6% 37,002 808.9 4 New York NY 1,628,701 21 0.5% 3,219 1976.4 4
Brazil 212,559,417 6 2.7% 169,183 795.9 5 Wayne MI 1,753,893 19 0.5% 3,154 1798.3 5
Mexico 128,932,753 10 1.7% 101,676 788.6 6 Nassau NY 1,358,343 29 0.4% 2,240 1649.1 6
USA 331,002,651 3 4.2% 257,072 776.6 7 Middlesex MA 1,614,714 22 0.5% 2,385 1477.0 7
France 65,273,511 22 0.8% 49,307 755.4 8 Suffolk NY 1,481,093 26 0.5% 2,032 1372.0 8
Colombia 50,882,891 29 0.7% 35,287 693.5 9 Miami-Dade FL 2,761,581 7 0.8% 3,766 1363.7 9
Iran 83,783,942 19 1.1% 45,255 540.1 10 Philadelphia PA 1,584,138 23 0.5% 1,952 1232.2 10
Poland 37,846,611 38 0.5% 13,774 363.9 11 Cook IL 5,180,493 2 1.6% 6,303 1216.7 11
South Africa 59,734,218 24 0.8% 20,903 349.9 12 Palm Beach FL 1,485,941 25 0.5% 1,648 1109.1 12
Canada 37,742,154 39 0.5% 11,535 305.6 13 Oakland MI 1,259,201 33 0.4% 1,310 1040.3 13
Iraq 40,222,493 36 0.5% 11,996 298.2 14 Maricopa AZ 4,410,824 4 1.3% 3,896 883.3 14
Ukraine 43,851,044 33 0.6% 11,423 260.5 15 Hennepin MN 1,259,428 32 0.4% 1,080 857.5 15
Russia 145,934,462 9 1.9% 36,192 248.0 16 Broward FL 1,951,260 17 0.6% 1,626 833.3 16
Germany 84,339,067 17 1.1% 14,277 169.3 17 Clark NV 2,231,647 13 0.7% 1,690 757.3 17
Turkey 83,992,949 18 1.1% 12,511 149.0 18 Bexar TX 1,986,049 16 0.6% 1,473 741.7 18
Morocco 36,910,560 40 0.5% 5,396 146.2 19 Los Angeles CA 10,105,518 1 3.1% 7,438 736.0 19
India 1,380,004,385 2 17.7% 133,738 96.9 20 Harris TX 4,698,619 3 1.4% 2,965 631.0 20
Philippines 109,581,078 13 1.4% 8,173 74.6 21 Hillsborough FL 1,436,888 27 0.4% 884 615.2 21
Egypt 102,334,404 14 1.3% 6,548 64.0 22 Cuyahoga OH 1,243,857 35 0.4% 734 590.1 22
Indonesia 273,523,615 4 3.5% 16,002 58.5 23 Riverside CA 2,450,758 10 0.7% 1,400 571.3 23
Algeria 43,849,260 34 0.6% 2,294 52.3 24 Dallas TX 2,637,772 8 0.8% 1,492 565.6 24
Afghanistan 38,928,346 37 0.5% 1,695 43.5 25 Fairfax VA 1,150,795 38 0.4% 614 533.5 25
Bangladesh 164,689,383 8 2.1% 6,416 39.0 26 San Bernardino CA 2,171,603 14 0.7% 1,127 519.0 26
Pakistan 220,892,340 5 2.8% 7,696 34.8 27 Franklin OH 1,310,300 31 0.4% 664 506.8 27
Myanmar 54,409,800 26 0.7% 1,765 32.4 28 Orange CA 3,185,968 6 1.0% 1,551 486.8 28
Sudan 43,733,762 35 0.6% 1,197 27.4 29 Tarrant TX 2,084,931 15 0.6% 982 471.0 29
Kenya 53,771,296 27 0.7% 1,392 25.9 30 Orange FL 1,348,975 30 0.4% 625 463.3 30
Japan 126,476,461 11 1.6% 1,949 15.4 31 Mecklenburg SC 1,093,901 40 0.3% 429 392.2 31
Ethiopia 114,963,588 12 1.5% 1,651 14.4 32 Allegheny PA 1,218,452 36 0.4% 475 389.8 32
South Korea 51,269,185 28 0.7% 509 9.9 33 Travis TX 1,248,743 34 0.4% 476 381.2 33
Nigeria 206,139,589 7 2.6% 1,167 5.7 34 King WA 2,233,163 12 0.7% 847 379.3 34
Uganda 45,195,774 32 0.6% 172 3.8 35 Sacramento CA 1,540,975 24 0.5% 546 354.3 35
DR Congo 89,561,403 16 1.1% 329 3.7 36 Salt Lake UT 1,152,633 37 0.4% 377 327.1 36
China 1,439,323,776 1 18.5% 4,742 3.3 37 Alameda CA 1,666,753 20 0.5% 499 299.4 37
Thailand 69,799,978 20 0.9% 60 0.9 38 San Diego CA 3,343,364 5 1.0% 966 288.9 38
Vietnam 97,338,579 15 1.2% 35 0.4 39 Santa Clara CA 1,937,570 18 0.6% 463 239.0 39
Tanzania 59,308,690 25 0.8% 21 0.4 40 Contra Costa CA 1,150,215 39 0.4% 257 223.4 40
Totals: 6,448,947,037 82.7% 1,179,251 88,652,927 27.1% 83,437December 2020 | Volume 10 | Article 605334
Capoor et al. Colds Our Ally Against SARS-CoV-2Data has consistently shown that children who become infected
with SARS-CoV-2 typically experience mild or no symptoms.
There may be multiple reasons for this clinical outcome,
including the lack of comorbidities and/or age-related immune
system characteristics. However, an intriguing possibility is that
cross-reactive T-cells generated in response to HCoV-related
colds may be present at a higher prevalence within the younger
population due to exposure in school environments (Arroll, 2011;
Steinman et al., 2020). It may be possible that these “circulating”
cross-reactive T-cells could suppress the development of clinical
symptoms, despite a recent study demonstrating that viral nucleic
acid loads in 5- to 17-year-oldsmatch or exceed (for those less than
5 years old) those found in adults (Heald-Sargent et al., 2020). It is
also unclear to what extent infected children shed SARS-CoV-2 or
are vectors for its spread, especially those who are symptom-free.
Studies to date have suggested that children, especially those in
primary or elementary schools, are at low risk of contracting the
disease, may be the initial source of infection in only a very
small number of cases, and are unlikely to pass it on via child-
to-child or child-to-adult transmission (Armann et al., 2020,
Davies et al., 2020; Munro and Faust, 2020; Posfay-Barbe
et al., 2020).T-CELL RESPONSES TO SARS-COV-2
IN NON-INFECTED AND ASYMPTOMATIC
INDIVIDUALS
While T-cell responses to SARS-CoV-2 in infected individuals
have now been reported, the emerging descriptions of pre-
existing SARS-CoV-2 cross-reactive CD4+ and CD8+ T-cells
amongst individuals who have not been infected are of
particular interest (Corman et al., 2018; Braun et al., 2020;
Grifoni et al., 2020; Sette and Crotty, 2020). The presence of
these cross-reactive T-cells appears to be explained by prior
exposure to HCoVs, such as HCoV-HKU1, HCoV-OC43H,
CoV-NL63, and HCoV-229E, that generate T-cells capable of
recognizing SARS-CoV-2 antigens (Mateus et al., 2020). Though
involving different viruses, a similar situation is reminiscent in the
historical findings of physician Edward Jenner, who discovered
that milkmaids rarely succumbed to smallpox and correctly
deduced that exposure to cowpox, a related virus causing a
much milder illness, protected them. Similarly, during the 2009
swine flu pandemic caused by H1N1/09, the majority of people
over the age of 60 displayed levels of pre-existing immunity
resulting from exposure to similar flu viruses earlier in life, while
young individuals had very little immunity and were, in contrast
to the current situation, at greater risk (Xu et al., 2010).
Immunocompetent children and adults with respiratory
infections (the common cold) often present as asymptomatic,
or develop mild respiratory tract illnesses. More than 200 viral
strains have been implicated as causal factors of the common
cold. Rhinoviruses are responsible for ~35% of upper respiratory
infections; HCoVs, often asymptomatic, cause 15-25% of cases,
while influenza, adenoviruses, and other viral types account for
the rest. Adults average two to three common colds each year,Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 3while children get six to eight, of which one or two are caused by
HCoVs (Simasek and Blandino, 2007). Accordingly, it was found
in a study of 100 subjects that most individuals had evidence of
serum antibodies to all four HCoV strains (Gorse et al., 2010).
We envisage one potential study resulting from a synthesis of
these observations could be to investigate whether levels of
longer-lasting “immunity” to SARS-CoV-2 could be higher
than serology tests indicate. A positive result would be
welcome news from a public health perspective.
Our ability to measure HCoV CD4+ and CD8+ T-cell
responses to SARS-CoV-2 infection is limited due to the
specialized nature of the tests. This major knowledge gap
makes the interpretation of COVID-19 disease pathogenesis
more difficult and clouds our ability to quantify the usefulness
of pandemic control measures, such as social distancing.CURRENT DATABASES DO NOT
CAPTURE SEVERITY OF SYMPTOMS AND
COHABITATION DATA
Searches of relevant publicly available databases, including the
Johns Hopkins Coronavirus Resource Centre, National Institutes
of Health Open-Access Data and Computational Resources to
Address COVID-19, CDC World Dataset, The Covid-19
Tracking Project, Florida Department of Health, New York
City Department of Health and Mental Hygiene, 1Point3Acres,
and others, revealed a lack of information relating to the severity
of symptoms (symptomatic vs. asymptomatic), possibly related
to lower testing rates in highly populated or developing countries
for individuals who are asymptomatic. More importantly,
information pertaining to cohabitation and contact tracing was
not included. A retrospective analysis that combines information
from SARS-CoV-2 patient and contact tracing databases might
be useful in determining whether individuals infected with
SARS-CoV-2 who reside with school-age children are more
likely to be asymptomatic. Such an analysis could be used to
test the hypothesis that exposure to HCoV in densely populated
environments leads to greater levels of cross-immunity to SARS-
CoV-2.THE NEED TO INCLUDE ASYMPTOMATIC
INDIVIDUALS IN SURVEILLANCE STUDIES
Surveillance studies of respiratory virus circulation in the United
States (and globally) are typically limited to data collected by
clinical labs from symptomatic individuals. This approach does
not capture the impact of respiratory infections that are
asymptomatic or associated with mild respiratory tract illness
in immunocompetent children and adults. The largest such
surveillance study of symptomatic HCoV patients, which was
conducted in the U.S. from 1st July, 2014 through 30th June, 2017,
contained the results of 854,575 HCoV rRT-PCR tests performed
by 117 laboratories in 42 states. Overall, 2·2% were positive for
HCoV-OC43, 1·0% for HCoV-NL63, 0·8% for HCoV-229E, andDecember 2020 | Volume 10 | Article 605334
Capoor et al. Colds Our Ally Against SARS-CoV-20·6% for HCoV-HKU1 (Killerby et al., 2018). These data suggest
that less than about 5% of symptomatic HCoV infections (colds)
are likely to help build cross-immunity to SARS-CoV-2.
For a different perspective we turn to a unique, cross-sectional
longitudinal study of individuals, both symptomatic and
asymptomatic, that sought to identify changes in respiratory
virus colonization before and after the 2013 Hajj, a 5- to 6-day
religious pilgrimage to Mecca, Saudi Arabia (attended by
more than 2 million people) (Memish et al., 2015). Pre- and
post-Hajj nasal specimens were prospectively obtained from a
paired cohort (692 pilgrims) and from nonpaired cohorts (514
arriving and 470 departing pilgrims) from 13 countries including
the United States (8·4%) and countries in Africa (44·2%), Asia
(40·2%), and Europe (7·2%). Nasal specimens were tested for 34
respiratory pathogens using RT-PCR. The prevalence of viruses
increased from 7·4% before the Hajj to 45·4% after the Hajj, due
to the acquisition of rhinoviruses, coronaviruses (229E, HKU1,
OC43), and influenza A H1N1. Among the paired cohort, HCoV
229E infections increased from six to 101 (0·9%–14·6%; p <
0·001). Among the non-paired cohort, HCoV 229E infections
increased from five to 48 (1·0%–10·2%; p < 0·001). These data,
taken from both symptomatic and asymptomatic adults, show
that HCoV 229E can, given the right conditions, spread
extremely quickly in a short period of time. This supports the
hypothesis that children, and potentially the adults with whom
they live, are likely to have been exposed to HCoV strains that
can elicit T-cells cross-reactive to SARS-CoV-2, perhaps leading
to a clinically relevant easing of symptoms. However, acquiring
the information needed to truly test the hypothesis, and make
more informed decisions, necessitates the inclusion of data from
both asymptomatic and symptomatic patients, SARS-CoV-2
databases, and surveillance systems.CONCLUSION
It may be the case that seasonal HCoV colds have actually been,
and will continue to be, one of our greatest allies in the fight
against the current SARS-CoV-2 pandemic and possibly SARS-
CoV-1 which surfaced in November 2002 (Feng et al., 2009).
Given other HCoVs are likely to provide levels of protection
against SARS-CoV-2 via cross-reactive immune memory, it is
important to maintain levels of immunity to the broader
spectrum of HCoVs in the current environment. If the spread
of other mild respiratory and HCoV-related infections in schoolFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 4is reduced from normal levels, what impact will this have on the
normal transmission of the “common cold” between children
and those with whom they reside, as well as the wider
community? Could this lead to a reduction in the temporary
buildup of cross-reactive T-cell responses to SARS-CoV-2 that
could provide some vital protection in an older, higher risk
population, particularly given the reduced level of T-cell diversity
and loss of immunity to previous HCoV infections as individuals
age? While speculative at this stage, it is possible that differential
spread of respiratory viruses other than SARS-CoV-2 within the
younger population could be beneficial for their older relatives.
Besides specialized research labs there is a limited ability to
measure HCoV CD4+ and CD8+ T-cell responses to SARS-
CoV-2 infection. This major knowledge gap currently impedes
interpretation of COVID-19 disease pathogenesis, and the
calibration of pandemic control measures including social
distancing. Unfortunately, the data needed to demonstrate this
is not available because current SARS-CoV-2 databases and
surveillance systems do not include information about the
people who might be benefitting from cross-reactive immune
memory ie., those who are asymptomatic. Inclusion of this data
could help paint a more accurate picture of the clinical course of
the SARS-CoV-2 pandemic and enable better decision making.DATA AVAILABILITY STATEMENT
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